Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Welcome and Introduction to Vi3C

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Oct
09
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves First-Line Pirtobrutinib for CLL-SLL
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
Charles Perou 2026 William L. McGuire Memorial Lecture Award
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo